$TENX News

Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5

Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4

Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients - Slideshow

William Blair Downgrades Tenax Therapeutics to Market Perform

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Tenax Therapeutics Reports Phase 3 LEVEL Trial Of TNX‑103 In PH‑HFpEF; Study Did Not Meet Primary Or Key Secondary Endpoints

Tenax Therapeutics: Double Or Nothing (Rating Upgrade)

Tenax Therapeutics Q2 EPS $(0.35) Beats $(0.37) Estimate

Canaccord Genuity Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $35

Evercore ISI Group Initiates Coverage On Tenax Therapeutics with Outperform Rating, Announces Price Target of $39

Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics To Present Results From Phase 3 LEVEL Clinical Trial In Late-Breaking Clinical Science Session At ESC Congress 2026

Cantor Fitzgerald Reiterates Overweight on Tenax Therapeutics, Maintains $35 Price Target

Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $40

Chardan Capital Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $27

Piper Sandler Maintains Overweight on Tenax Therapeutics, Raises Price Target to $50